Novo Nordisk reported positive Phase 3 results today for its semaglutide pill, marking a key step toward expanding diabetes treatment for younger patients. The late-stage trial, known as PIONEER TEENS, tested the oral drug in children aged...
Shares of Alembic Pharmaceuticals edged up 1.09 percent to Rs 772.55 after the company revealed plans to strengthen its global footprint with a new subsidiary in Southeast Asia. The move signals Alembic Pharmaceuticals’ continued push into...
Amneal Pharmaceuticals has announced a major acquisition deal worth up to $1.1 billion acquisition to acquire Kashiv BioSciences, strengthening its presence in the fast-growing biosimilars market. The move reflects the increasing focus among pharm...
A team at National Institute of Technology Rourkela has developed a new bio-ink for 3D bioprinting, offering fresh potential for pharmaceutical research and tissue engineering. The bio-ink for 3D bioprinting is engineered to improve both...
The Government of India is stepping up efforts to strengthen healthcare infrastructure while focusing on the early diagnosis of non-communicable diseases (NCDs), Union Health Minister Jagat Prakash Nadda said during a recent policy discussion.
India’s pharmaceutical industry is well-equipped to deal with short-term supply disruptions, according to the Central Government, which says strong domestic production of key raw materials provides stability during global uncertainty.
India and Brazil on Saturday signed a India-Brazil MoU to strengthen cooperation in regulating pharmaceutical and medical products, marking a key move to deepen health sector ties. The agreement was formalized at Hyderabad House between Central...
Indian pharmaceutical company Lupin Limited has expanded its presence in the U.S. healthcare market with the launch of a diabetes medication after receiving approval from the United States Food and Drug Administration.
Supriya Lifescience Limited has received a major regulatory boost as the U.S. Food and Drug Administration issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification for its API manufacturing unit in...
Bharat Parenterals Ltd said its subsidiary, Innoxel Lifesciences, has received five observations from the United States Food and Drug Administration (USFDA) following a recent USFDA inspection at its Vadodara facility.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")